On Oct. 10, 2022, Novavax announced that Switzerlands Federal Office of Public Health had recommended Nuvaxovidﾙ(NVX-CoV2373) as a heterologous and homologous booster for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 in adults aged 18 and older. The FOPH now recommends use of Nuvaxovid as an adult booster regardless of previous vaccine history as part of its autumn 2022 COVID-19 vaccine booster campaign.